Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Ariel Small Cap Value Strategy Ariel Investments, LLC | “Charles River Laboratories International, Inc. ($CRL), representing 3.4% of the composite, provides early-stage contract research services, animal models, and clinical discovery support for global pharmaceutical and biotechnology corporations. Ariel maintains a bullish stance following an earnings beat and full-year guidance upgrade. The manager's core thesis is anchored on early-cycle indicators of stabilization in biotechnology funding markets, which position the company for a sustained rebound in preclinical discovery demand. Economically, Charles River functions as an essential, high-barrier-to-entry research partner with a wide regulatory and technical moat. The business displays robust operating leverage as biopharma clients scale pipeline activity. Management's portfolio optimization and deployment of automation within Manufacturing Solutions have expanded operating margins and cash flow conversion. These internal efficiency initiatives, combined with active share repurchases and a conservative balance sheet, reinforce long-term return on invested capital. Primary catalysts include the cyclical recovery in broad biopharmaceutical research and development expenditures and accelerating net bookings within Discovery & Safety Assessment. Key risks include ongoing volatility in early-stage biotech venture financing and regulatory scrutiny surrounding preclinical laboratory testing.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Ariel Fund John W. Rogers, Jr. | “Charles River Laboratories ($CRL) provides essential preclinical laboratory testing, animal models, and drug discovery research services to biotechnology and pharmaceutical firms, accounting for 4.6% of fund assets. The manager maintains a high-conviction bullish stance as the contract research organization benefits from an early turnaround in life sciences capital deployment. CRL benefits from high barriers to entry and customer switching costs, creating a durable economic moat anchored by regulatory compliance requirements. Operating leverage is expanding via internal automation within Manufacturing Solutions and targeted portfolio optimizations, supporting robust return on invested capital alongside opportunistic share repurchases financed from strong free cash flow. Primary catalysts involve sustained stabilization and recovery in broad biopharmaceutical venture funding and clinical R&D expenditure. Key downside risks include lingering budgetary caution among early-stage biotech clients and potential volatility in regulatory drug approval velocity.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Ariel Appreciation Fund John W. Rogers | “Charles River Laboratories ($CRL), which represents 3.9% of the fund's portfolio, is an essential contract research organization providing discovery and safety assessment services, laboratory products, and manufacturing support to the global biopharmaceutical industry. The manager holds a high-conviction bullish stance on the company, expecting CRL to capture compounding value as broader biopharma research funding markets stabilize and customer procurement recovers. The core financial thesis rests on the company's operating leverage and expanding profit margins. As baseline discovery demand inflects upward, CRL's high fixed-cost infrastructure converts incremental revenue into substantial operating earnings growth. Management's strategic portfolio optimization, efficiency programs, and manufacturing automation initiatives provide strong margin expansion, further augmented by aggressive capital return via share repurchases supported by a sturdy corporate balance sheet. Key upside catalysts include sustained recovery in venture-backed biotechnology funding and expanded enterprise biopharma R&D budgets. Primary risks center on prolonged softness in early-stage preclinical funding, regulatory delays in customer pipelines, and broader capital constraints within the life sciences sector.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Madison Dividend Income Fund John Brown, Drew Justman | “Our investments in drug development companies like Charles River Labs (CRL) and Medpace Holdings (MEDP) pulled back, driven by AI disruption fears. Our work suggests disruption fears are overexaggerat” | BULL | Q1 2026 Apr 18, 2026 | View Pitch |
Invesco Small Cap Value Fund Jonathan Edwards, Jonathan Mueller | “Charles River Laboratories was added as a new position. This leading CRO supports the discovery, development and safe manufacture of new drugs, biologics, vaccines and medical devices. It has a diversified portfolio with exposure to high growth therapeutic areas. Slower spending on biotech and pharma research and development has been a headwind to the stock, which gave us an opportunity to invest at what we saw as an attractive discount to our estimate of intrinsic value. BSD Analysis: Charles River Laboratories is positioned for a significant recovery in 2026 as biopharma R&D spending stabilizes following a post-pandemic correction. The company maintains a "Buy" consensus from the majority of analysts, with projections indicating a significant upside from its 52-week lows. For 2026, the investment case is bolstered by the firm's dominant position in the early-stage drug discovery and safety assessment market, which serves as a prerequisite for nearly all clinical trials. Management is successfully leveraging AI-powered data analytics to improve lead optimization and reduce drug development timelines for its clients. While operating margins faced some pressure during the previous cycle, the company's aggressive cost-management and capacity optimization are expected to drive margin expansion through 2026. The stock's current valuation is viewed as attractive by institutional investors, particularly as biotech funding begins to show a sustained rebound. For 2026, Charles River remains a core holding for those betting on the long-term industrialization of drug discovery.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Ariel Appreciation Fund John W. Rogers | “Charles River Laboratories (CRL) also traded higher on solid quarterly results, reinforcing its position as a leader in outsourced drug development services. While biotech funding and large pharma budgets have moderated, outsourcing demand remains resilient and we believe CRL's scale and capabilities position it well for recovery. Although near-term growth is pressured as big pharma prioritizes clinical programs over nonclinical work, we view these shifts as temporary since nonclinical testing is essential to replenishing pipelines. Longer term, CRL's diversified portfolio and investments in high-growth areas like cell and gene therapy support durable growth and margin expansion. The company is streamlining operations, divesting non-core assets and maintaining leverage below 3x, while a new $1B share repurchase authorization underscores confidence in its outlook. Despite macro uncertainty and near-term headwinds, we believe CRL's market opportunity is large, regulated and enduring; and its breadth and pricing power position it for renewed growth as demand normalizes. BSD Analysis: Charles River is a backbone supplier to drug discovery, embedded so deeply in R&D workflows that switching is often impractical. Biotech funding slowdowns hit volumes, but they don't eliminate demand — they delay it. The company benefits disproportionately when funding cycles turn back on. Its breadth across discovery, safety assessment, and manufacturing services creates cross-selling advantages. Margin pressure has exposed operating leverage in both directions. Investors treat current weakness as structural rather than cyclical. The installed base and regulatory complexity protect long-term relevance. As pipelines restart, utilization snaps back quickly. This is a picks-and-shovels name temporarily priced like broken equipment.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Madison Small Cap Fund Faraz Farzam, Aaron Garcia | “We initiated a position in Charles River Labs in Q3. CRL is a high-quality company in the drug discovery and development outsourcing space with a broad range of services from basic research to contract manufacturing. The company has operating margins of 20% or more and generates substantial free cash flow. The past few years have been challenging for companies in the drug development space, as capital has become increasingly constrained and research and development spending has remained stagnant. However, CRL has the operating history and mix of businesses to be successful over the long term. The customer base is diverse and CRL benefits from the increased dynamics of outsourcing by its biopharmaceutical clients. The company's top line has grown at a 12% compound annual rate over the last 10 years, even with the recent downturn. Management is solid, and we've known them for decades. We believe Charles River's earnings power can reach approximately $15 in 2028, assuming modest growth. We also use a sum of the parts at ~12x EBITDA (earnings before interest, taxes, depreciation, and amortization) to assess the attractiveness of CRL. This implies an intrinsic value of $228. Importantly, we think we are being conservative, as we don't build in a resumption of double-digit revenue growth in our valuation framework. However, we anticipate revenue growth of 4% from 2024 to 2028 and a modest margin recovery, aided by restructuring and cost-outs. BSD Analysis: Charles River still sits at the center of preclinical drug development, with scale and scientific breadth that smaller CROs can't touch. Biopharma funding softness has created noise, but backlog quality and specialty services remain strong. Regulatory overhangs have moderated, and margins are improving as capacity normalizes. Despite temporary headwinds, CRL remains a mission-critical partner in the pharma value chain. The stock is priced for stagnation; the business is anything but.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.